The most significant difference I've found between Veyonda and Opaganib are in their dosages and routes of administration. I'm looking forward to the release of the pharmacokinteic study for NOX66 since this will us how good this treatment really could be, but since NOX are looking to boost their dosage to 2400mg in the DARRT-2 study, I would hazard a guess to say the PK results must be very positive.
Here is a poster presentation for anyone interested in seeing some PK data for Veyonda:
https://www.noxopharm.com/site/PDF/9c5b37e0-2fe7-4549-91aa-5631602d3f0b/IdronoxillevelsofpatientsreceivingNOX66
Competitors, page-5
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.5¢ | 10.5¢ | $2.964K | 26.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 53298 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 33616 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| NOX (ASX) Chart |